METOCURINE

US Previously Marketed

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C40H48N2O6
Molecular Weight	652.8189
Optical Activity	UNSPECIFIED
Defined Stereocenters	2 / 2
E/Z Centers	0
Charge	2

SHOW SMILES / InChI

Structure Search

SMILES

COC1=CC=C2C[C@@H]3C4=C(OC5=CC=C(C[C@H]6C7=C(CC[N+]6(C)C)C=C(OC)C(OC1=C2)=C7)C=C5)C(OC)=C(OC)C=C4CC[N+]3(C)C

InChI

InChIKey=JFXBEKISTKFVAB-AJQTZOPKSA-N

InChI=1S/C40H48N2O6/c1-41(2)17-15-27-22-34(44-6)36-24-30(27)31(41)19-25-9-12-29(13-10-25)47-40-38-28(23-37(45-7)39(40)46-8)16-18-42(3,4)32(38)20-26-11-14-33(43-5)35(21-26)48-36/h9-14,21-24,31-32H,15-20H2,1-8H3/q+2/t31-,32+/m0/s1

HIDE SMILES / InChI

Description
Sources: http://www.hmdb.ca/metabolites/HMDB0015429 | https://www.ncbi.nlm.nih.gov/pubmed/3161430

Metocurine, also known as dimethyltubocurarine, is a non-depolarizing muscle relaxant through the neuromuscular blockade. It antagonizes the neurotransmitter action of acetylcholine by binding competitively with cholinergic receptor sites on the motor end-plate. Patients chronically receiving anticonvulsants are relatively resistant to metocurine.

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
neuromuscular 4 Target ID: neuromuscular Sources: https://www.ncbi.nlm.nih.gov/pubmed/7023284	Blocker 537

Conditions

Condition	Modality	Targets	Highest Phase	Product
skeletal muscle relaxation 7 Sources: https://www.drugbank.ca/drugs/DB00416	Primary		Approved 8429	METOCURINE IODIDE Approved Use Metocurine iodide is a benzylisoquinolinium competitive nondepolarizing neuromuscular blocking agent. It is used as an anesthesia adjunct to induce skeletal muscle relaxation and to reduce the intensity of muscle contractions in convulsive therapy Metocurine iodide has a moderate risk of inducing histamine release and has some ganglion blocking activity. Metocurine iodide can be used most advantageously if muscle twitch response to peripheral nerve stimulation is monitored to assess degree of muscle relaxation. Metocurine Iodide is no longer available on the US market.

C_max

Value	Dose	Co-administered	Analyte	Population
0.46 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7023284/	0.3 mg/kg single, intravenous dose: 0.3 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered:		METOCURINE serum	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
1.05 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7023284/	0.3 mg/kg single, intravenous dose: 0.3 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered:		METOCURINE serum	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

T_1/2

Value	Dose	Co-administered	Analyte	Population
6 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7023284/	0.3 mg/kg single, intravenous dose: 0.3 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered:		METOCURINE serum	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
11.4 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7023284/	0.3 mg/kg single, intravenous dose: 0.3 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered:		METOCURINE serum	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

Sourcing

Vendor/Aggregator	ID	URL
ABI Chem	AC1L2HW8
Alfa Chemistry	ACM33335589
BLD Pharm	BD01166218	http://www.bldpharm.com/products/5152-30-7.html
BOC Sciences	7601-55-0
Bosche Scientific	T1675
Compound Cloud	21233
Compound Cloud	24244
NCI Plated 2007	36388
NovoSeek	21233
Specs	AE-562/43459779
Tetrahedron	TS75701
ZINC	ZINC000004097448	http://zinc15.docking.org/substances/ZINC000004097448
eMolecules	260195514
eMolecules	260536772
eMolecules	36726843

PubMed

Title	Date	PubMed
Rocuronium-induced neuromuscular block is affected by chronic carbamazepine therapy.	1999 Jan	9915319
Curariform antagonists bind in different orientations to the nicotinic receptor ligand binding domain.	2003 Aug 22	12799358
Curariform antagonists bind in different orientations to acetylcholine-binding protein.	2003 Jun 20	12682067
Roles of amino acids and subunits in determining the inhibition of nicotinic acetylcholine receptors by competitive antagonists.	2007 Jun	17525594
Synergy between pairs of competitive antagonists at adult human muscle acetylcholine receptors.	2008 Aug	18633030
Reduced blood pressure lability during emergence from anaesthesia in rats: a pilot study using clonidine.	2008 Feb	17995999
Site selectivity of competitive antagonists for the mouse adult muscle nicotinic acetylcholine receptor.	2009 Jan	18842832
Impact of anti-cancer drugs and other determinants on serum protein binding of morphine 6-glucuronide.	2010	22615603
Development of a list of potentially inappropriate drugs for the korean elderly using the delphi method.	2010 Dec	21818443

Name

Type

Language

METOCURINE

Common Name

English

13H-4,6:21,24-DIETHENO-8,12-METHENO-1H-PYRIDO(3',2':14,15)(1,11)DIOXACYCLOEICOSINO(2,3,4-IJ)ISOQUINOLINIUM, 2,3,13A,14,15,16,25,25A-OCTAHYDRO-9,18,19,29-TETRAMETHOXY-1,1,14,14-TETRAMETHYL-, (13AR,25AS)-

Common Name

English

Dimethyltubocurarinium [WHO-DD]

Common Name

English

O,O-DIMETHYL-(+)-TUBOCURARINE

Common Name

English

DIMETHYL TUBOCURARINE

Common Name

English

6,6',7',12'-TETRAMETHOXY-2,2,2',2'-TETRAMETHYLTUBOCURARAN-2,2'-DIIUM

Common Name

English

METOCURINE CATION

Common Name

English

TUBOCURARANIUM, 6,6',7',12'-TETRAMETHOXY-2,2,2',2'-TETRAMETHYL-

Common Name

English

METOCURINE ION

Common Name

English

DIMETHYLTUBOCURARINIUM

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C29696